BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 24366758)

  • 21. Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer.
    Wang J; Xu R; Li J; Bai Y; Liu T; Jiao S; Dai G; Xu J; Liu Y; Fan N; Shu Y; Ba Y; Ma D; Qin S; Zheng L; Chen W; Shen L
    Gastric Cancer; 2016 Jan; 19(1):234-44. PubMed ID: 25604851
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II study of cetuximab plus S-1/cisplatin therapy in Japanese patients with advanced gastric cancer.
    Yamaguchi K; Fuse N; Komatsu Y; Fujii H; Hironaka S; Omuro Y; Muro K; Yasui H; Ueda S; Nishina T; Watanabe M; Ohtsu A
    Jpn J Clin Oncol; 2021 May; 51(6):879-885. PubMed ID: 33561262
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Docetaxel and Cisplatin Plus Fluorouracil compared with Modified Docetaxel, Cisplatin, and 5-Fluorouracil as first-line therapy for advanced gastric cancer: a retrospective analysis of single institution.
    Inal A; Kaplan MA; Kucukoner M; Isikdogan A
    Neoplasma; 2012; 59(2):233-6. PubMed ID: 22248282
    [TBL] [Abstract][Full Text] [Related]  

  • 24. S-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study.
    Li YH; Qiu MZ; Xu JM; Sun GP; Lu HS; Liu YP; Zhong MZ; Zhang HL; Yu SY; Li W; Hu XH; Wang JJ; Cheng Y; Zhou JT; Guo ZQ; Guan ZG; Xu RH
    Oncotarget; 2015 Oct; 6(33):35107-15. PubMed ID: 26439700
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oral fluoropyrimidines (capecitabine or S-1) and cisplatin as first line treatment in elderly patients with advanced gastric cancer: a retrospective study.
    Seol YM; Song MK; Choi YJ; Kim GH; Shin HJ; Song GA; Chung JS; Cho GJ
    Jpn J Clin Oncol; 2009 Jan; 39(1):43-8. PubMed ID: 18997184
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I study of docetaxel, cisplatin and S-1 in patients with advanced gastric cancer.
    Hironaka S; Yamazaki K; Taku K; Yokota T; Shitara K; Kojima T; Ueda S; Machida N; Muro K; Boku N
    Jpn J Clin Oncol; 2010 Nov; 40(11):1014-20. PubMed ID: 20603245
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multicenter phase II study of trastuzumab plus S-1 alone in elderly patients with HER2-positive advanced gastric cancer (JACCRO GC-06).
    Kimura Y; Fujii M; Masuishi T; Nishikawa K; Kunisaki C; Matsusaka S; Segawa Y; Nakamura M; Sasaki K; Nagao N; Hatachi Y; Yuasa Y; Asami S; Takeuchi M; Furukawa H; Nakajima T;
    Gastric Cancer; 2018 May; 21(3):421-427. PubMed ID: 28936560
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial.
    Yoshida K; Kodera Y; Kochi M; Ichikawa W; Kakeji Y; Sano T; Nagao N; Takahashi M; Takagane A; Watanabe T; Kaji M; Okitsu H; Nomura T; Matsui T; Yoshikawa T; Matsuyama J; Yamada M; Ito S; Takeuchi M; Fujii M
    J Clin Oncol; 2019 May; 37(15):1296-1304. PubMed ID: 30925125
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical Benefit and Health-Related Quality of Life Assessment in Patients Treated with Cisplatin/S-1 Versus Cisplatin/5-FU: Secondary End Point Results From the First-Line Advanced Gastric Cancer Study (FLAGS).
    Bodoky G; Scheulen ME; Rivera F; Jassem J; Carrato A; Moiseyenko V; Vynnychenko I; Prausová J; Van Laethem JL; Cascinu S; Ajani JA
    J Gastrointest Cancer; 2015 Jun; 46(2):109-17. PubMed ID: 25707610
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized phase II study of a combination of docetaxel and S-1 versus docetaxel monotherapy in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy: results of Okayama Lung Cancer Study Group (OLCSG) Trial 0503.
    Segawa Y; Kiura K; Hotta K; Takigawa N; Tabata M; Matsuo K; Yoshioka H; Hayashi H; Kawai H; Aoe K; Maeda T; Ueoka H; Tanimoto M
    J Thorac Oncol; 2010 Sep; 5(9):1430-4. PubMed ID: 20651615
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase II study of weekly docetaxel and cisplatin plus oral tegafur/uracil and leucovorin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer.
    Li CP; Chen JS; Chen LT; Yen CJ; Lee KD; Su WP; Lin PC; Lu CH; Tsai HJ; Chao Y
    Br J Cancer; 2010 Oct; 103(9):1343-8. PubMed ID: 20924378
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of stage IV gastric cancer with induction chemotherapy using S-1 and cisplatin followed by curative resection in selected patients.
    Saito M; Kiyozaki H; Takata O; Suzuki K; Rikiyama T
    World J Surg Oncol; 2014 Dec; 12():406. PubMed ID: 25551581
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study.
    Boku N; Yamamoto S; Fukuda H; Shirao K; Doi T; Sawaki A; Koizumi W; Saito H; Yamaguchi K; Takiuchi H; Nasu J; Ohtsu A;
    Lancet Oncol; 2009 Nov; 10(11):1063-9. PubMed ID: 19818685
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial.
    Yamada Y; Boku N; Mizusawa J; Iwasa S; Kadowaki S; Nakayama N; Azuma M; Sakamoto T; Shitara K; Tamura T; Chin K; Hata H; Nakamori M; Hara H; Yasui H; Katayama H; Fukuda H; Yoshikawa T; Sasako M; Terashima M
    Lancet Gastroenterol Hepatol; 2019 Jul; 4(7):501-510. PubMed ID: 31101534
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase III trial comparing oral S-1/cisplatin and intravenous 5-fluorouracil/cisplatin in patients with untreated diffuse gastric cancer.
    Ajani JA; Abramov M; Bondarenko I; Shparyk Y; Gorbunova V; Hontsa A; Otchenash N; Alsina M; Lazarev S; Feliu J; Elme A; Esko V; Abdalla K; Verma U; Benedetti F; Aoyama T; Mizuguchi H; Makris L; Rosati G;
    Ann Oncol; 2017 Sep; 28(9):2142-2148. PubMed ID: 28911091
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
    Van Cutsem E; Moiseyenko VM; Tjulandin S; Majlis A; Constenla M; Boni C; Rodrigues A; Fodor M; Chao Y; Voznyi E; Risse ML; Ajani JA;
    J Clin Oncol; 2006 Nov; 24(31):4991-7. PubMed ID: 17075117
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase II study of modified docetaxel, cisplatin, and S-1 (mDCS) chemotherapy for unresectable advanced gastric cancer.
    Uemura N; Kikuchi S; Sato Y; Ohnuma H; Okamoto K; Miyamoto H; Hirakawa M; Sagawa T; Fujikawa K; Takahashi Y; Okuda T; Minami S; Takahashi M; Okamoto T; Takada K; Miyanisi K; Takayama T; Kato J
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):707-713. PubMed ID: 28849257
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multicenter phase II study of S-1 and docetaxel combination chemotherapy for advanced or recurrent gastric cancer patients with peritoneal dissemination.
    Shigeyasu K; Kagawa S; Uno F; Nishizaki M; Kishimoto H; Gochi A; Kimura T; Takahata T; Nonaka Y; Ninomiya M; Fujiwara T
    Cancer Chemother Pharmacol; 2013 Apr; 71(4):937-43. PubMed ID: 23355040
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer).
    Nokihara H; Lu S; Mok TSK; Nakagawa K; Yamamoto N; Shi YK; Zhang L; Soo RA; Yang JC; Sugawara S; Nishio M; Takahashi T; Goto K; Chang J; Maemondo M; Ichinose Y; Cheng Y; Lim WT; Morita S; Tamura T
    Ann Oncol; 2017 Nov; 28(11):2698-2706. PubMed ID: 29045553
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase II study of preoperative chemotherapy with docetaxel, cisplatin, and S-1 followed by gastrectomy with D2 plus para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis: JCOG1002.
    Ito S; Sano T; Mizusawa J; Takahari D; Katayama H; Katai H; Kawashima Y; Kinoshita T; Terashima M; Nashimoto A; Nakamori M; Onaya H; Sasako M
    Gastric Cancer; 2017 Mar; 20(2):322-331. PubMed ID: 27299887
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.